乌司奴单抗治疗炎症性肠病的临床进展  

Clinical progress of Ustekinumab in the treatment of inflammatory bowel disease

作　　者：程鑫 金奕婕 童锦禄[1] CHENG Xin;JIN Yijie;TONG Jinlu(Department of Gastroenterology,Renji Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200001,China)

机构地区：[1]上海交通大学医学院附属仁济医院消化内科,上海200001

出　　处：《胃肠病学和肝病学杂志》2023年第6期687-689,共3页Chinese Journal of Gastroenterology and Hepatology

摘　　要：炎症性肠病以慢性复发性肠道炎症为特征,主要包括克罗恩病和溃疡性结肠炎。除了传统的抗TNF制剂外,越来越多的新型生物制剂应用于炎症性肠病的治疗。IL-12以及IL-23是在介导肠道炎症的过程中起着重要作用的两种细胞因子。靶向抑制IL-12和IL-23的共同亚基p40的乌司奴单抗是一种全人源单克隆抗体制剂,国内外研究表明,乌司奴单抗在中重度克罗恩病和溃疡性结肠炎的治疗中显著改善患者临床症状,同时具有良好的耐受性和安全性。Inflammatory bowel disease,characterized by chronic relapsing intestinal inflammation,is mainly consisted of Crohn′s disease and ulcerative colitis.In addition to the traditional TNF antagonists,more and more new biological agents are used in the treatment of inflammatory bowel disease.IL-12 and IL-23 are two cytokines that play an important role in mediating intestinal inflammation.Ustekinumab is a kind of humanized monoclonal biological agent targeting p40 which is the shared subunit of IL-12 and IL-23.It has been reported that Ustekinumab has shown excellent performance in the treatment of moderate to severe Crohn′s disease and ulcerative colitis.Ustekinumab can not only improve patients′clinical symptoms significantly,but also show a good tolerability and safety.

关 键 词：炎症性肠病 IL-12 IL-23 乌司奴单抗 

分 类 号：R574.6[医药卫生—消化系统]